Postmenopausal osteoporosis, breast cancer, and aromatase inhibitor

Osteoporose pós-menopausa, câncer de mama e o inibidor da aromatase

CORRESPONDENCE

Postmenopausal osteoporosis, breast cancer, and aromatase inhibitor

Osteoporose pós-menopausa, câncer de mama e o inibidor da aromatase

Somsri Wiwanitkit^I; Viroj Wiwanitkit^II

^IWiwanitkit House, Bangkhae, Bangkok, Thailand

^IIHainan Medical University, China, Faculty of Medicine, University of Nis, Serbia, Joseph Ayobabalola University, Nigeria

^{Corresponding author}

Dear Editor,

The recent article on bone mineral density in postmenopausal women with and without breast cancer was very interesting. Conde et al. concluded that The prevalence of abnormal bone mineral density (BMD) was higher in postmenopausal breast cancer survivors (BCS) than in postmenopausal women without breast cancer".¹ Certainly, the concern regarding osteoporosis in the cancerous patient is very important. As Conde et al. mentioned, "special vigilance and the adoption of interventions should be instituted early to minimize bone loss". Indeed, cancer therapy should also be focused on monitoring osteoporosis among cancerous patients. The use of aromatase inhibitor as an adjuvant therapy in breast cancer is quite intriguing.² It was recently reported that the use of aromatase inhibitor significantly increased osteoporosis, especially at femur region.²

Conflicts of interest

The authors declare no conflicts of interest.

• 1. Conde DM, Costa-Paiva L, Martinez EZ, Pinto-Neto AM. Bone mineral density in postmenopausal women with and without breast cancer. Rev Assoc Med Bras. 2012;58(6):673-8.
• 2. Mutlu H, Aslan T, Yılmaz GS, Erden A, Cihan YB, Akca Z, et al. Osteoporosis associated with aromatase inhibitors is different from post-menopausal osteoporosis. Adv Lab Med Int. 2013;3(1):1-5.

Publication Dates

• Publication in this collection
  05 July 2013
• Date of issue
  June 2013